+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Tocilizumab"

From
From
Rheumatoid Arthritis Market and Forecast Analysis to 2025 - Product Thumbnail Image

Rheumatoid Arthritis Market and Forecast Analysis to 2025

  • Drug Pipelines
  • August 2018
  • 610 Pages
  • Global
From
Systemic Idiopathic Juvenile Arthritis - Pipeline Review, H2 2019 - Product Thumbnail Image

Systemic Idiopathic Juvenile Arthritis - Pipeline Review, H2 2019

  • Drug Pipelines
  • November 2019
  • 58 Pages
  • Global
From
Loading Indicator

Tocilizumab is a monoclonal antibody used to treat immune disorders, such as rheumatoid arthritis, juvenile idiopathic arthritis, systemic juvenile idiopathic arthritis, and giant cell arteritis. It works by blocking the action of interleukin-6, a protein that plays a role in inflammation. It is administered intravenously or subcutaneously. Common side effects include upper respiratory tract infections, headache, and nausea. Tocilizumab is a relatively new drug, having been approved by the US Food and Drug Administration in 2010. It is used to treat a variety of immune disorders, and is often used in combination with other drugs. It has been found to be effective in reducing inflammation and improving symptoms in patients with rheumatoid arthritis and other immune disorders. Several companies are involved in the Tocilizumab market, including Roche, Chugai Pharmaceuticals, and Eli Lilly. These companies manufacture and distribute the drug, as well as provide support services to healthcare providers and patients. Show Less Read more